AMEX Biotechnology Stock
Antares Pharma, Inc. (“Antares” or the “Company”) is a specialized pharma product development
and pipeline company with patented drug delivery platforms including Advanced Transdermal Delivery (ATD™) gels, fast-melt oral (Easy Tec™) tablets, disposable mini-needle injection systems (Vibex™), and reusable needle-free injection
systems (VISION ® AND ...
more
We are a development stage biopharmaceutical company that is developing a pipeline of hormone therapy products to treat men and women. We also are engaged in the development of our proprietary calcium phosphate nanotechnology, or CAP, for vaccine adjuvants or immune system boosters and drug delivery systems.
more
We are a product-based biopharmaceutical company engaged in the development of small molecule drugs to treat and prevent cardiovascular disease and diabetes. We identified several promising product candidates that we believe represent novel approaches to some of the largest pharmaceutical markets. We have advanced one of these products into Phase 2 clinical trials.
more
The information contained
in this section on business is qualified in its entirety by, and is subject to,
the detailed information, consolidated financial statements and notes thereto
contained elsewhere within this document.
more
We are a biotechnology-driven company with the primary goal of becoming a leader in the emerging biomass-to-ethanol industry. We produce ethanol and its co-products.
more
,” and Item 7 “Management’s
Discussion and Analysis of Financial Condition and Results of Operations,” and the documents
incorporated by reference, include forward-looking statements within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. All statements, other than ...
more
Javelin Pharmaceuticals, Inc. is engaged in the research and development of products for the
pain management market. Unless the context otherwise requires, all references in this report to
“Javelin”, “Company”, “we”, “us” or “our” include Javelin Pharmaceuticals, Inc., and any ...
more
Simulations Plus, Inc. (the "Company" or "Simulations Plus", or "we" or "our") and its wholly owned subsidiary, Words+, Inc. ("Words+") produce different types of products: (1) Simulations Plus, incorporated in 1996, develops and produces software for use in pharmaceutical research and for education, and also provides contract research services to the pharmaceutical industry, and (2) Words+, ...
more
We
are an
ophthalmic product development company focused on ophthalmic pharmaceutical
products based on our proprietary DuraSite® eyedrop-based drug delivery
technology, as well as the development of genetically-based technologies for
the
diagnosis, prognosis and management of glaucoma.
more
CONDUCT GUIDELINES
EX-21.1 LIST OF SUBSIDIARIES
EX-23.1 CONSENT OF BDO SEIDMAN, LLP
EX-31.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER
EX-31.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER
EX-32.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
more
This Annual Report contains forward-looking statements
regarding our business, financial condition, results of
operations and prospects. Words such as “expects,”
“anticipates,” “intends,” “plans,”
“believes,” “seeks,” “estimates”
and similar expressions or variations of such words are intended ...
more
We are a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics.
more
We are engaged in the discovery and development of novel
therapeutics that modulate immune responses through Toll-like
Receptors, or TLRs, for the treatment of multiple diseases. We
have developed proprietary DNA-and RNA-based compounds that
modulate TLRs and are targeted to TLR7, TLR8 or TLR9. We believe
that these immune modulatory oligonucleotides, or
IMO tm ...
more
In this Annual Report on Form 10-K, references to "dollars" and "$" are to United States Dollars. References to "we", "us", the "Company" or "Tiens USA" include Tiens Biotech Group (USA), Inc. and its subsidiaries.
more
